Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4- carboxamide and of its 7-chloro derivative: The roles of topoisomerases I and II

Cancer Chemotherapy and Pharmacology

Volumn 43, Issue 4, 1999, Pages 302-308

  Bridewell, David J A ^a   Finlay, Graeme J ^a   Baguley, Bruce C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Acridine; Amsacrine; Camptothecin; Cell cycle; Dual topoisomerase inhibitors

Indexed keywords

ACRIDINE DERIVATIVE; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE; CYTOTOXICITY; DRUG MECHANISM; LUNG NON SMALL CELL CANCER; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR;

ACRIDINES; AMSACRINE; ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; DNA DAMAGE; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; ENZYME INHIBITORS; HUMANS; KINETICS; LUNG NEOPLASMS; MICE; MODELS, CHEMICAL; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0033048874     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050899     Document Type: Article

References (23)

1. 1. Atwell GJ, Rewcastle GW, Baguley BC, Denny WA (1987) Potential antitumor agents. 50. In vivo solid tumor activity of derivatives of N-[12-(dimethylamino)ethyl]acridine-4-carboxamide. J Med Chem 30: 664-669
2. 2. Berger JM, Gamblin SJ, Harrison SC, Wang JC (1996) Structure and mechanism of DNA topoisomerase II. Nature 379: 225-232
3. 3. Bridewell DJA, Finlay GJ, Baguley BC (1997) Differential actions of aclarubicin and doxorubicin: the role of topoisomerase I. Oncol Res 9: 535-542
4. 4. Costa M, Zhitkovich A, Taioli E, Toniolo P (1993) Preliminary report on a simple new assay for DNA-protein cross-links as a biomarker of exposures experienced by welders. J Toxicol Environ Health 40: 217-222
5. 5. D'Arpa P, Liu LF (1989) Topoisomerase-targeting antitumor drugs. Biochim Biophys acta 989: 163-177
6. 6. Davey RA, Su GM, Hargrave RM, Harvie RM, Baguley BC, Davey MW (1997) The potential of N-[12-(dimethylamino)ethyl]acridine-4-carboxamide to circumvent three multidrug-resistance phenotypes in vitro. Cancer Chemother Pharmacol 39: 424-430
7. 7. Finlay GJ, Wilson WR, Baguley BC (1989) Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs. Eur J Cancer Clin Oncol 25: 1695-1701
8. 8. Finlay GJ, Marshall ES, Matthews JHL, Paull KD, Baguley BC (1993) In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance. Cancer Chemother Pharmacol 31: 401-406
9. 9. Finlay GJ, Riou J-F, Baguley BC (1996) From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine 4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Eur J Cancer 32A: 708-714
10. 10. Haldane A, Finlay GJ, Gavin JB, Baguley BC (1992) Unusual dynamics of killing of cultured Lewis lung cells by the DNA-intercalating antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. Cancer Chemother Pharmacol 29: 475-479
11. 11 Haldane A, Finlay GJ, Baguley BC (1993) A comparison of the effects of aphidicolin and other inhibitors on topoisomerase II-directed cytotoxic drugs. Oncol Res 5: 133-138
12. 12. Jensen PB, Sorensen BS, Demant EJ, Sehested M, Jensen PS, Vindelov L, Hansen HH (1990) Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res 50: 3311-3316
13. 13. McGhee JD, Hippel PH von (1974) Theoretical aspects of DNA-protein interactions: co-operative and non-co-operative binding of large ligands to a one-dimensional homogeneous lattice. J Mol Biol 86: 469-491
14. 14. Nitiss JL, Pourquier P, Pommier Y (1997) Aclacinomycin A stabilizes topoisomerase I covalent complexes. Cancer Res 57: 4564-4569
15. 15. Rowe T, Kupfer G, Ross W (1985) Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA cleavage. Biochem Pharmacol 34: 2483-2487
16. 16. Schneider E, Darkin SJ, Lawson PA, Ching L-M, Ralph RK, Baguley BC (1988) Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II. Eur J Cancer Clin Oncol 24: 1783-1790
17. 17. Sorensen BS, Jensen PB, Sehested M, Jensen PS, Kjeldsen E, Nielsen OF, Alsner J (1994) Antagonistic effect of aclarubicin on camptothecin induced cytotoxicity: role of topoisomerase I. Biochem Pharamacol 47: 2105-2110
18. 18. Stevnsner T, Mortensen UH, Westergaard O, Bonven BJ (1989) Interactions between eukaryotic DNA topoisomerase I and a specific binding sequence. J Biol Chem 264: 10110-10113
19. 19. Tanizawa A, Pommier Y (1992) Topoisomerase-I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. Cancer Res 52: 1848-1854
20. 20. Wang JC (1996) DNA topoisomerases. Annu Rev Biochem 64: 635-692
21. 21. Wilson WR, Baguley BC, Wakelin LPG, Waring MJ (1981) Interaction of the antitumour drug m-AMSA (4′-(9-acridinylamino) methanesulphon-m-anisidide) and related acridines with nucleic acids. Mol Pharmacol 20: 404-414
22. 22. Woessner RD, Eng WK, Hofmann GA, Rieman DJ, McCabe FL, Hertzberg RP, Mattern MR, Tan KB, Johnson RK (1992) Camptothecin hyper-resistant P388 cells - drug-dependent reduction in topoisomerase-I content. Oncol Res 4: 481-488
23. 23. Zhitkovich A, Costa M (1992) A simple, sensitive assay to detect DNA-protein crosslinks in intact cells and in vivo. Carcinogenesis 13: 1485-1489